AADI (Aadi Bioscience) Earnings growth in current year

Official company branding of Aadi Bioscience, Inc. (AADI)

Optimized express logistics for pharmaceuticals are driving momentum, as confirmed by the 12-month relative EPS growth rate; the value 78.50 represents the current metric. The fundamental basis of Aadi Bioscience (AADI) is the unique Fyarro therapy for rare tumors. Robotic cell screening, which minimizes headcount, enhances development efficiency. Certified air corridors ensure the precision of drug delivery.

AADI (Aadi Bioscience Inc) Earnings growth in current year history from 07/04/2022 to 03/19/2025

Comprehensive metric breakdowns and analytics for aadibio.com (AADI)

- share price and expert price forecast:
Price Aadi Bioscience, Inc.|AADI - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization AADI|AADI - Total Company Value
- book capitalization data:
Accounting Value of a Share Aadi Bioscience|AADI - Book Capitalization|Market Value to Equity Ratio aadibio.com|AADI - Company Total Assets
- debt and liquidity details:
Debt to Capital Aadi Bioscience|AADI - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Aadi Bioscience, Inc.|AADI - Company Aggregate Debts|Debts to Book Value AADI|AADI - Company Long-Term Debts|Company Short-Term Indebtedness Aadi Bioscience|Intermediate Coverage Ratio aadibio.com
- net income and valuation multiples indicators:
AADI - Net Income|Future Net Profit Aadi Bioscience|AADI - P/E Multiple|Future Price to Earnings Multiple Aadi Bioscience, Inc.|AADI - PEG Multiple|Company Value to EBITDA AADI|AADI - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Aadi Bioscience|AADI - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth aadibio.com|AADI - Earnings per share growth in current year|Net earnings per share change forecast for next year Aadi Bioscience
Fundamental valuation:AADI Aadi Bio
Signature product of Aadi Bioscience

Geopolitical fragmentation and the disruption of supply chains significantly hinder the conduct of international clinical trials for Aadi Bioscience (AADI). By analyzing the year-over-year percentage growth in net income per share, investors assess business efficiency dynamics relative to the previous period. This metric calculates the percentage difference between current and prior EPS, determining the company's ability to generate income amidst external risks and its operational resilience.

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Corp) - Earnings growth in current year|Earnings growth in current year Nuvalent Therapeutics|Earnings per share growth in current year Kymera Therapeutics (KYMR)|IDYA (ideayabio.com) - Earnings per share increase in current year|Earnings growth in current year ELVN (Enliven Therapeutics, Inc.)|Net earnings per share change in current year ORIC Pharmaceuticals Inc|Relay Pharma - Earnings growth in current year|Earnings per share growth rate in current year Nurix Corp|TYRA (Tyra Biosciences, Inc.) - Net earnings per share growth this year|VSTM: Net earnings per one share growth for the current year|GLUE (Monte Rosa Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Cullinan Oncology CGEM|Earnings growth in current year IMRX|C4 Therapeutics Corp - Earnings per share growth this year|Black Diamond - Net earnings per share growth this year|Earnings per share increase in current year RPTX|PMVP: Net earnings per share growth this year|Karyopharm Therapeutics - Net earnings per one share growth for the current year|PPCB: Earnings growth in current year|Cyclacel - Earnings per share increase in current year|ALRN (Aileron Therapeutics Inc) - Earnings growth in current year|Earnings per share growth rate in current year Blueprint Medicines Corp BPMC|Earnings per share growth in current year GlycoMimetics, Inc. (GLYC)|SWTX (SpringWorks Therapeutics Inc.) - Earnings per share increase in current year